The European Personalised Medicine Diagnostics Association (EPEMED) has appointed its founding board of directors.
Chairman and founder of the association is Alain Huriez, chief executive of TcLand Expression, a molecular diagnostic company dedicated to personalised medicine diagnostics in immunology (solid organ transplantation and immune mediated disorders), located in Nantes France.
The other board members are: Mara Aspinall, ceo of On-Q-ity; Vincent Fert, ceo of Ipsogen; Werner Kroll, head of diagnostics research and innovation at Novartis Molecular Diagnostics; Iain Miller, senior director of oncology strategy and theranostics at bioMerieux; Herman Spolders, ceo of Oncomethylome Sciences; and Patrick Terry, ceo of Technic Solutions.
The association was formed in August to help make personalised medicine a reality. Personalised medicine, the use of a person's clinical, genetic, genomic and environmental information to select more accurately a medication and its dose for each individual patient, is expected to improve care and lower costs.
EPEMED has members from the diagnostic, pharmaceutical, device and academic communities, in addition to patient groups and professional service firms. It aims to:
Move forward the field of personalised medicine across Europe through the sharing of ideas and business models;
Provide leadership on policies related to personalised medicine in Europe;
Promote harmonisation in the approach to personalised medicine across Europe;
Create joint programmes with other international personalised medicine organisations.